Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (May 2017)
19 slides from Adalta's investor presentation, May 3, 2017
Slide 1: ASX Announcement: Updated AdAlta Investor Presentation
ASX ANNOUNCEMENT Updated AdAlta Investor Presentation For personal use only MELBOURNE Australia, 3 May, 2017: AdAlta Limited (ASX:1AD), the biotechnology Company advancing its lead i-body candidate towards clinical development today announced an updated investor presentation that Chief Executive Off
Slide 2: Notes to Editors: About AdAlta
Notes to Editors About AdAlta AdAlta Limited is an Australian based drug development company headquartered in For personal use only Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeut
Slide 3: i-bodies – a new class of protein therapeutics to treat human disease
For personal use only i-bodies – a new class of protein therapeutics to treat human disease May 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) [email protected]
Slide 4: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 5: Corporate and investment summary
Corporate and investment summary A drug discovery and development company For personal use only Capital structure using its powerful technology platform to ASX code 1AD generate a promising new class of protein Shares on issue* 101,110,890 therapeutics, known as i-bodies, for treating a Share price
Slide 6: i-body technology
i-body technology Long loop that enables access to For personal use only AdAlta is developing a new technology platform that produces novel drug targets unique proteins known as i-bodies, that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks
Slide 7: Fibrosis: unmet medical need with multiple indications
Fibrosis: unmet medical need with multiple indications For personal use only Developing i-bodies as improved therapies for the treatment of fibrosis – a condition that is prevalent in 45-50% of all diseases Fibrosis can occur in many tissues of the body Lung Eye Liver as a result of inflammation or
Slide 8: AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF)
AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF) For personal use only AD-114 is lead i-body candidate in pre-clinical development – Demonstrates both anti- fibrotic and anti-inflammatory activity in the lung – Important for arresting and modifying the disease and tackling the treatment of
Slide 9: AD-114 prevents lung fibrosis in disease models
AD-114 prevents lung fibrosis in disease models For personal use only Extensive pre-clinical AD-114 studies have demonstrated positive in vitro (in the lab) and in vivo (in animals) data Normal IPF lung tissue IPF lung tissue + AD-114 lung tissue (lung disease mouse model) dosed for 21 days (lung di
Slide 10: AD-114 key advantages compared to existing IPF treatments
AD-114 key advantages compared to existing IPF treatments For personal use only AD-114 has greater in vitro efficacy compared to the only No effect Effect on approved therapies Nintedanib and Pirfenidone for IPF Human tissue on normal diseased / treatment In vitro activity tissue IPF tissue – Existi
Slide 11: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments Recent transactions confirm that big pharma are actively acquiring fibrosis assets at For personal use only an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-15 Adheron SDP051 Roche $
Slide 12: AD-114 broad application for treatment of fibrosis
AD-114 broad application for treatment of fibrosis For personal use only Wet-AMD AMD is the leading cause of blindness in people over the age of 50 years in the developed world, >1m in AU and 2m in USA Despite anti-VEGF therapy (US$8 billion sales 2016), 30% of people don’t respond and 50% of people
Slide 13: AD-114 development: key milestones
AD-114 development: key milestones For personal use only CY2017 CY2018 Q1 Q2 Q3 Q4 Q1 Q2 Partnering of lead Manufacturing candidate Toxicology studies based on other benchmark deals Orphan designation Phase I Publication of data Other fibrosis indications BD and partnerships 11
Slide 14: Recent achievements and near term milestones
Recent achievements and near term milestones For personal use only Q3 & Q4 2016 ü Commence manufacturing of material for toxicology testing with FujiFilm Diosynth Biotechnologies ü Additional AD-114 IPF fibrosis data ü Completion of evaluation of AD-114 with IPF clinicians Alfred Hospital ü Completi
Slide 15: AdAlta business model – strategy to create value
AdAlta business model – strategy to create value For personal use only Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 16: Market benchmarks
Market benchmarks For personal use only Fibrosis lead AD-114 Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen antibodies April-16 with Abbvie Dec -15 with Roche Nov-15
Slide 17: Management and Board in place to deliver strategy
Management and Board in place to deliver strategy For personal use only Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Extensive experience in raising equity, contract and CEO of investment Company NewStar Ventures grant funding Managing Director of acquired antibody compa
Slide 18: Scientific Advisory Board
Scientific Advisory Board Internationally recognised with proven track record of drug development For personal use only Dr Mick Foley, AdAlta CSO John Westwick: pulmonary drug Expert in phage display discovery and development NIH, NHMRC, ARC, Gates funding and over 70 Over 14 years experience at Nov
Slide 19: AdAlta investment summary
AdAlta investment summary For personal use only Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases Initial focus on treating Idiopathic Pulmonary Fibrosis and other fibrotic diseases - high unmet clinical need Advanced lead